SS-31 Peptide in NYC: Targeting the Mitochondria to Combat Aging at Its Source

The mitochondria are the power plants of the cell — and their decline is one of the most fundamental drivers of aging across every tissue and organ system. At Regen Health Physicians (RHPNY) in New York City, our peptide therapy portfolio includes SS-31 (also known as Elamipretide or MTP-131), a small synthetic tetrapeptide that directly targets the inner mitochondrial membrane and demonstrates remarkable protective and restorative effects in both preclinical and clinical research.

What Is SS-31 (Elamipretide)?

SS-31 is a cell-permeable tetrapeptide (D-Arg-2′6′-Dmt-Lys-Phe-NH2) developed by Dr. Hazel Szeto at Cornell University. Unlike most molecules that cannot cross the mitochondrial membranes, SS-31 is specifically engineered to concentrate at the inner mitochondrial membrane — targeting the precise location where mitochondrial aging and dysfunction occur.

Its primary molecular target is cardiolipin — a phospholipid unique to the inner mitochondrial membrane that is essential for the proper assembly and function of the electron transport chain (ETC). Cardiolipin deteriorates significantly with age and in disease states, and its dysfunction is a central driver of mitochondrial inefficiency.

How SS-31 Works

1. Cardiolipin Stabilization

SS-31 binds to cardiolipin and prevents its oxidation by cytochrome c — a reaction that impairs electron transport and drives reactive oxygen species (ROS) generation. By stabilizing cardiolipin, SS-31 preserves optimal ETC function and dramatically reduces mitochondrial ROS output.

2. ATP Production Enhancement

By restoring ETC efficiency, SS-31 increases ATP production — the cellular energy currency. In aging tissues, declining ATP is a core driver of fatigue, cognitive impairment, muscular weakness, and impaired repair.

3. Reduction of Oxidative Stress

The inner mitochondrial membrane is the primary source of cellular ROS. By preventing cardiolipin oxidation and maintaining ETC integrity, SS-31 reduces the oxidative burden that damages mtDNA, proteins, and lipids throughout the cell.

4. Mitochondrial Morphology Preservation

SS-31 has been shown to preserve the elongated, fused mitochondrial networks associated with high function — preventing the fragmentation that characterizes aging and disease.

Clinical and Preclinical Evidence

SS-31 has moved into clinical trials (as Elamipretide) for several conditions, including:

• Heart failure: Phase II trials showed significant improvements in exercise capacity and cardiac function in patients with heart failure with reduced ejection fraction
• Barth Syndrome: A mitochondrial cardiomyopathy — clinical trials showed dramatic functional improvements in affected children
• Aging-related sarcopenia: Preclinical studies demonstrate improvements in muscle function, mitochondrial respiration, and exercise capacity in aged animals
• Chronic kidney disease: Renal ischemia-reperfusion models show significant protection with SS-31
• Neurodegenerative disease models: Alzheimer's and Parkinson's disease animal models show reduced amyloid burden and improved neurological function

In longevity research, SS-31 administered to aged mice restored mitochondrial function to levels approaching young animals and significantly improved physical performance and health markers.

Clinical Applications at RHPNY

At RHPNY, SS-31 is considered for patients with:

• Profound fatigue not attributable to other causes — particularly the flat, unrelenting fatigue of mitochondrial insufficiency
• Cardiovascular aging — declining exercise tolerance, VO2 max reduction
• Post-COVID fatigue — where mitochondrial dysfunction is increasingly implicated as a core mechanism
• Sarcopenia — age-related muscle loss where mitochondrial energetics are a primary driver
• Neurocognitive aging — brain fog, memory changes, cognitive fatigue
• Longevity optimization — as part of a comprehensive anti-aging protocol

Our peptide therapy program evaluates each patient's clinical picture, mitochondrial function markers, and goals before recommending SS-31 or any other advanced peptide.

Administration

SS-31 is administered subcutaneously. Typical protocols in clinical research have used daily or multiple-times-weekly injection schedules. At RHPNY, Dr. Dhaliwal tailors the dose and frequency to the patient's indication, response, and tolerance.

SS-31 is often combined with:

• NAD+ therapy: Addresses the NAD+/NADH ratio, which is a separate but complementary driver of mitochondrial efficiency
• CoQ10: Supports ETC function through a different mechanism than SS-31
• [BPC-157 and other tissue peptides](/peptides): For patients with systemic inflammation driving mitochondrial dysfunction
• [Hormone optimization](/chronic-disease): Thyroid hormone, testosterone, and estrogen all significantly influence mitochondrial biogenesis through PGC-1α pathway regulation

A Note on Regulatory Status

SS-31/Elamipretide is in active clinical trials and is not yet FDA-approved as a therapeutic agent in the United States. At RHPNY, it is offered within the framework of a supervised physician-patient relationship, with full transparency about its investigational status and the clinical evidence base.

Take the Next Step

If you are in New York City or Salt Lake City and interested in mitochondrial optimization as part of your longevity and health strategy, book a consultation with Dr. Ajit Dhaliwal at RHPNY. We will evaluate whether SS-31 and related mitochondrial therapies are appropriate for your individual situation.

---

Medical Disclaimer: SS-31 (Elamipretide) is an investigational peptide not yet FDA-approved for clinical use. This content is for educational purposes only and does not constitute medical advice. All peptide therapy decisions should be made under the supervision of a qualified physician.